- Home
- TSI vs CANF Comparison
TSI vs CANF Comparison
Compare TSI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSI | CANF |
|---|---|---|
| Founded | 1987 | 1994 |
| Country | United States | Israel |
| Employees | N/A | 5 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.7M | 4.7M |
| IPO Year | 1995 | 2011 |
Fundamental Metrics
Financial Performance| Metric | TSI | CANF |
|---|---|---|
| Price | $4.61 | $3.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | 308.5K | ★ 634.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | $290,391.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.57 | $0.17 |
| 52 Week High | $5.06 | $10.40 |
Technical Indicators
Market Signals| Indicator | TSI | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 36.96 | 40.57 |
| Support Level | $4.58 | $0.60 |
| Resistance Level | $4.96 | $4.74 |
| Average True Range (ATR) | 0.04 | 0.71 |
| MACD | 0.01 | -0.19 |
| Stochastic Oscillator | 27.62 | 1.16 |
Price Performance
Historical ComparisonAbout TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.